REVEAL trial: VASCAZEN meets primary endpoint

Apr 10 2013

Pivotal Therapeutics Inc. (OTCQX: PVTTF) (CNSX: PVO), a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease (CVD) and overall health, is pleased to announce that VASCAZEN^® met its primary endpoint in the REVEAL trial. Additionally, VASCAZEN^® achieved statistical significance in various secondary endpoints in patients presenting with elevated triglycerides (>200mg/dL < 500mg/dL). The data has been accepted for presentation at the American Heart Association's Arteriosclerosis, Thrombosis and Vascular Biology (ATVB) 2013 Scientific Sessions (ATVB) at Lake Buena Vista, Florida, USA, May 1-3, 2013.

"This data represents a significant milestone for VASCAZEN^® as a treatment option for the thousands of people who are Omega-3 defeicient and suffer from elevated triglycerides yet remain below the threshold of "very high" triglycerides required for treatment with currently available prescription medications" said Dr. George Jackowski , Chairman and Chief Scientific Officer. "This landmark study is among the first that examined Omega-3 deficiency pre and post treatment and brings the importance of its correction to the forefront as an important part in managing CVD patients.  We are very excited to be presenting our top line results at this premier conference as it attracts the top clinicians and scientists in all areas of cardiovascular disease focusing on lipids and heart disease."

Dr. Jackowski gratefully acknowledges the outstanding contribution of the Contract Research Organization (CRO), Nutrasource Diagnostics Inc., Guelph, Ontario, Canada, for its professional execution and management of the VASCAZEN^®-REVEAL trial.  "The CRO trial team has done a superb job in the overall management of this pivotal study," stated Dr. Jackowski.